

T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019

<https://marketpublishers.com/r/T6230A53EF7EEN.html>

Date: November 2019

Pages: 84

Price: US\$ 3,500.00 (Single User License)

ID: T6230A53EF7EEN

Abstracts

T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019

SUMMARY

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019, outlays comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - T-Cell surface glycoprotein CD3 epsilon chain also known as CD3E is a polypeptide encoded by the CD3E gene. T-cell surface glycoprotein CD3 epsilon chain interacts with TOP2B, CD3EAP and NCK2. The CD3 complex mediates signal transduction, resulting in T-cell activation and proliferation. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Metabolic Disorders, Gastrointestinal, Genetic Disorders, Immunology and Infectious Disease which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Sclerosis, Type 1 Diabetes

(Juvenile Diabetes), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Inflammation, Crohn's Disease (Regional Enteritis), Down Syndrome, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Hepatitis B, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Lymphoblastic Lymphoma, Multiple Myeloma (Kahler Disease), Nodal Marginal Zone B-Cell Lymphoma, Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Solid Tumor, Splenic Marginal Zone B-Cell Lymphoma, Traumatic Brain Injury and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Furthermore, this report also reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)

The report reviews T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which

includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics and enlists all their major and minor projects

The report assesses T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Overview

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development

Amgen Inc

Celgene Corp

F. Hoffmann-La Roche Ltd

Numab Innovation AG

Provention Bio Inc

SYNIMMUNE GmbH

Tiziana Life Sciences Plc

Tolerx, Inc. (Inactive)

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles

AMG-330 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Target CD3E and PSMA for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

blinatumomab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EM-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

foralumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to target CD3E and Cells Expressing NKG2D for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

otelixizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasotuxizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-7082859 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TACSYN - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teplizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Dormant Products

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Product Development Milestones

Featured News & Press Releases

Nov 06, 2019: Roche to present on its Non-Hodgkin Lymphoma drug candidate CD20-TCB at the American Society of Hematology 2019 Annual Meeting

Oct 24, 2019: Provention Bio announces PRV-031 (Teplizumab) granted PRIME designation by the European Medicines Agency

Sep 25, 2019: Amgen stops Blincyto's Phase III paediatric ALL trials early

Sep 24, 2019: Provention Bio reiterates regulatory strategy for PRV-031 and announces completion of follow-on financing

Sep 16, 2019: Tiziana Life Sciences announces FDA approval to initiate phase I clinical trial with orally administered foralumab in healthy volunteers

Sep 10, 2019: Tiziana reports phase 1 clinical data demonstrating nasal treatment with foralumab was well-tolerated and produced positive trend in biomarkers of immunomodulation and anti-inflammation in healthy volunteers

Aug 20, 2019: Provention Bio announces key addition to its leadership team

Aug 05, 2019: Provention Bio announces breakthrough therapy designation for Teplizumab (PRV-031) for the prevention or delay of clinical type 1 diabetes in at-risk individuals

Jul 01, 2019: Tiziana Life Sciences provides update on development on Foralumab

Jul 01, 2019: Independent Third Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes

Jun 24, 2019: Newly published article reporting clinical activity of orally administered OKT3, a mouse anti-CD3 monoclonal antibody, in moderate to severe ulcerative colitis patients, supports Tiziana's oral monoclonal antibody platform

Jun 15, 2019: Amgen announces BLINCYTO (blinatumomab) five-year overall survival data At EHA 2019

Jun 09, 2019: A Single course of Provention's PRV-031 (Teplizumab) delays Type 1 Diabetes Onset in High-Risk Individuals by at least two years

Jun 02, 2019: Amgen presented data on its investigational drug AMG 212 at ASCO

2019

May 29, 2019: Amgen to present on its prostate cancer drug candidate AMG 212 at 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Celgene Corp, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Numab Innovation AG, H2 2019
Pipeline by Provention Bio Inc, H2 2019
Pipeline by SYNIMMUNE GmbH, H2 2019
Pipeline by Tiziana Life Sciences Plc, H2 2019
Pipeline by Tolerx, Inc. (Inactive), H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Amgen Inc

Celgene Corp

F. Hoffmann-La Roche Ltd

Numab Innovation AG

Provention Bio Inc

SYNIMMUNE GmbH

Tiziana Life Sciences Plc

Tolerx, Inc. (Inactive)

I would like to order

Product name: T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/T6230A53EF7EEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T6230A53EF7EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970